AUTO-UPDATED

INmune Bio and Quantum Computing partner to apply quantum optimization and AI to advance Alzheimer’s drug research and explore new applications for XPro

INmune Bio and Quantum Computing Inc. have partnered to utilize the Dirac-3S quantum optimization machine to identify new therapeutic indications and biomarkers for the drug candidate XPro.

Key Points

  • INmune Bio will use QCi’s Dirac-3S quantum machine to analyze clinical data from four trials of its investigational Alzheimer’s treatment, XPro.
  • The collaboration aims to identify new disease targets for XPro, specifically focusing on rare diseases that may allow for faster, more capital-efficient clinical trials.
  • This agreement marks QCi’s first commercial entry into the pharmaceutical and biotechnology sectors.
  • Researchers will compare quantum optimization results against conventional machine-learning methods to evaluate the effectiveness of quantum computing in drug development.
  • The project seeks to establish a repeatable discovery process for identifying patient populations and biomarkers that predict positive treatment responses.

Why it Matters

This partnership represents a practical application of quantum computing in the pharmaceutical industry to accelerate drug discovery and optimize clinical trial design. By leveraging advanced data analytics, the companies aim to reduce the time and cost associated with identifying new therapeutic uses for existing drug candidates.
The Next Web Published by Technology Newswire
Read original